RxDoctor Payments Data

Joel Schuman, MD

Ophthalmology · Philadelphia, PANPI 1932184777

Payments from drug & device makers

$73,579in general payments, 2019–2025

Across 27 payments — averaging $2725.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$48K
  • Alcon Research LLC$16K
  • Nidek CO., LTD.$4K
  • Bausch & Lomb Americas Inc.$3K
  • Alcon$1K
  • Johnson & Johnson Surgical Vision, Inc.$1K
  • plus $342 from 5 others
$81in research payments, 2019–2025

Across 1 payment — averaging $81.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$81

What the payments were for

  • Consulting fees$8,47540%
  • Speaking & faculty fees$10,00047%
  • Travel & lodging$1,6488%
  • Food & beverage$1,1215%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$73,579 in reported general payments places this provider in the 90th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$84,502
Medicare patients
191
Services billed
770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Phospholine IodideEchothiophate Iodide17$44,282
RocklatanNetarsudil Mesylat/Latanoprost45$33,478
RhopressaNetarsudil Mesylate60$32,999
LumiganBimatoprost48$22,345
VyzultaLatanoprostene Bunod22$14,272
Alphagan PBrimonidine Tartrate18$10,774
SimbrinzaBrinzolamide/Brimonidine Tart38$9,939
CombiganBrimonidine Tartrate/Timolol22$9,471
Brimonidine Tartrate112$7,639
Brinzolamide19$5,437
Prednisolone Acetate134$5,310
Methazolamide14$5,147
Latanoprost308$4,611
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat212$4,032
Timolol Maleate77$3,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$50$66,477105 claims
Bausch & Lomb Americas Inc.Vyzulta$2,598$14,27222 claims
AlconSimbrinza$1,045$9,93938 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →